DDInter1628 DDInter1760
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Rux
Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.[A252937, A252942] Currently, telotristat ethyl is used to treat carcinoid syndrome diarrhea from neuroendocrine tumors that are inadequately controlled by short-acting somatostatin analog (SSA) treatment. Neuroendocrine cells are cells that secrete regulatory peptides and biogenic amines in response to chemical, neural, or other types of stimuli. Neuroendocrine tumors (NET) arising from these cells can therefore secrete chemical mediators into the bloodstream to cause side effects in distant sites, a phenomenon called carcinoid syndrome. The most common peptides and amines secreted by NET are histamines, tachykinins, kallikrein, and serotonin. Overexposure to serotonin can cause severe diarrhea, one of the main clinical symptoms of carcinoid syndrome. Serotonin is metabolized in the urinary metabolite 5-hydroxy indole acetic acid (u5-HIAA), and high levels of u5-HIAA is associated with poor survival outcome in patients with NET. The first line treatment of carcinoid syndrome diarrhea is SSA, but symptoms still reoccur over the course of the disease.
Ruxolitinib {u} (Compound) binds {v} (Gene) TAOK2
TAOK2 {u} (Gene) is bound by {v} (Compound) Sorafenib
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Telotristat ethyl
Ruxolitinib {u} (Compound) upregulates {v} (Gene) NFKBIA
NFKBIA {u} (Gene) is upregulated by {v} (Compound) Sorafenib
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Telotristat ethyl
Ruxolitinib {u} (Compound) binds {v} (Gene) MAP3K7
MAP3K7 {u} (Gene) is upregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Telotristat ethyl
Ruxolitinib {u} (Compound) downregulates {v} (Gene) PRKAG2
PRKAG2 {u} (Gene) is upregulated by {v} (Compound) Sorafenib
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Telotristat ethyl
Ruxolitinib {u} (Compound) upregulates {v} (Gene) NFKBIA
NFKBIA {u} (Gene) is downregulated by {v} (Compound) Albendazole
Albendazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Telotristat ethyl
Ruxolitinib {u} (Compound) downregulates {v} (Gene) PRKAG2
PRKAG2 {u} (Gene) is downregulated by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Telotristat ethyl
Ruxolitinib {u} (Compound) downregulates {v} (Gene) RPS6KA1
RPS6KA1 {u} (Gene) is bound by {v} (Compound) Sunitinib
Sunitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Telotristat ethyl
Ruxolitinib {u} (Compound) binds {v} (Gene) PLK1
PLK1 {u} (Gene) is downregulated by {v} (Compound) Sorafenib
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Telotristat ethyl
Ruxolitinib {u} (Compound) causes {v} (Side Effect) Hepatobiliary disease
Hepatobiliary disease {u} (Side Effect) is caused by {v} (Compound) Sorafenib
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Telotristat ethyl
Ruxolitinib {u} (Compound) upregulates {v} (Gene) HMGCR
HMGCR {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Simvastatin
Simvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Telotristat ethyl
Ruxolitinib (Compound) binds TAOK2 (Gene) and TAOK2 (Gene) is bound by Sorafenib (Compound) and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Ruxolitinib (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is upregulated by Sorafenib (Compound) and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Ruxolitinib (Compound) binds MAP3K7 (Gene) and MAP3K7 (Gene) is upregulated by Bortezomib (Compound) and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Ruxolitinib (Compound) downregulates PRKAG2 (Gene) and PRKAG2 (Gene) is upregulated by Sorafenib (Compound) and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Ruxolitinib (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is downregulated by Albendazole (Compound) and Albendazole may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Ruxolitinib (Compound) downregulates PRKAG2 (Gene) and PRKAG2 (Gene) is downregulated by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Ruxolitinib (Compound) downregulates RPS6KA1 (Gene) and RPS6KA1 (Gene) is bound by Sunitinib (Compound) and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Ruxolitinib (Compound) binds PLK1 (Gene) and PLK1 (Gene) is downregulated by Sorafenib (Compound) and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Ruxolitinib (Compound) causes Hepatobiliary disease (Side Effect) and Hepatobiliary disease (Side Effect) is caused by Sorafenib (Compound) and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Ruxolitinib (Compound) upregulates HMGCR (Gene) and HMGCR (Gene) is bound by Simvastatin (Compound) and HMGCR (Gene) is upregulated by Simvastatin (Compound) and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl